SNDX News and Press, Syndax Pharmaceuticals Inc. From 02/05/26

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim Emerg...

2026-01-13 01:25:59 ET Syndax Pharmaceuticals, Inc. (SNDX) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 6:00 PM EST... Read the full article on Seeking Alpha For further details see: Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan He...

 – Approximately $44 million and $125 million in preliminary (unaudited) Revuforj ® (revumenib) 4Q25 and full year 2025 net revenue, respectively –  – Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increas...

- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin America, and Africa - NEW YORK, Jan. 07...

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conferenc...

2025-12-22 08:30:48 ET Now that 2025 is nearing its close and the holidays are upon us, I want to wish readers a joyous year-end holiday season. You likely have festivities to attend (and I do too), but as the year winds down I wanted to close with my annual performance review. Busi...

2025-12-17 08:15:00 ET Syndax Pharmaceuticals (NASDAQ: SNDX ) has transitioned to a commercial stage biopharma company with two FDA approved drugs: Revuforj and Niktimvo . Revuforj is a first-in-class menin inhibitor approved for the treatment of relapsed or refractory (R/R)...

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline. The Best ...

2025-12-08 18:47:20 ET Syndax Pharmaceuticals, Inc. (SNDX) The 67th American Society of Hematology (ASH) Annual Meeting December 8, 2025 7:00 AM EST... Read the full article on Seeking Alpha For further details see: Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th Am...

– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts – – Retrospective review shows revumenib was well tol...